Loading clinical trials...
Loading clinical trials...
A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Conditions
Interventions
Lisdexamfetamine Dimesylate (LDX)
Locations
45
United States
Clinical Study Centers, LLC
Little Rock, Arkansas, United States
Valley Clinical Research, Inc.
El Centro, California, United States
Penninsula Research Associates, Inc.
Rolling Hills Estates, California, United States
Psychiatric Centers at San Diego (PCSD-Feighner Research Institute)
San Diego, California, United States
Elite Clinical Trials, Inc.
Wildomar, California, United States
Florida Clinical Research Center, LLC
Bradenton, Florida, United States
Start Date
November 13, 2008
Primary Completion Date
April 22, 2010
Completion Date
April 22, 2010
Last Updated
June 14, 2021
NCT07478458
NCT07465081
NCT07314333
NCT07189442
NCT06711224
NCT06221358
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions